Key facts
- It has raised $1.4M.
- Notable investors include University of California, Cornucopian Capital, Baszucki Group, San Diego.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Phenotap
- ·The full record, as it builds
Funding rounds
No funding rounds for Phenotap are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phenotap
Developer of breakthrough ketone-measurement technology designed to support reliable health and wellness monitoring. The company offers a proprietary enzyme for continuous ketone measurement and a non-invasive sensor that simplifies tracking of dietary and supplement effects, enabling consumers and nutrition-focused organizations to monitor metabolic responses and connect with suitable nutritional products for improved wellness outcomes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 4
- Website
- phenotap.com/
- Ownership
- Privately Held (backing)
Phenotap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phenotap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phenotap in its N-PORT filings yet. We sweep new filings monthly.